Emerging Company Profile
Ventyx emerges with $114M to bring asset-centric immunology plays under one umbrella
Emerging Company Profile: Oppilan, Zomagen and Ventyx merge to advance autoimmune, inflammation pipeline
Oppilan, Zomagen and Ventyx merge to advance autoimmune and inflammation pipeline with $114 million round led by venBio.
Ventyx is the second start-up in the past month to bundle asset-centric companies under one umbrella with an eye towards advancing each program faster than the originator companies could have had they remained independent. The company, which launched Tuesday